Sp389
PANEL DISCUSSION
Date
May 19, 2024
Tracks
Related Products
IBD Controlled Trials II
SOCIETY: AGA This session is the second session of the ever-popular and clinically impactful clinical trials sessions in IBD. Insights into novel agents including obefazimod, VTX002. MH002, risankizumab, and mirikizumab will be presented…
BOWEL URGENCY OUTCOMES ARE ASSOCIATED WITH IMPROVEMENT IN FATIGUE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A POOLED ANALYSIS OF LUCENT-1 AND LUCENT-2 PHASE 3 TRIALS
BACKGROUND: Cancer is a major cause of morbidity and mortality in persons with inflammatory bowel disease (IBD). We evaluated temporal trends and relative risks of intestinal and extra-intestinal cancers among persons with IBD and matched controls…
ENVIRONMENTAL AND DIETARY FACTORS IN INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED CASE-CONTROL STUDY FROM THE GLOBAL INFLAMMATORY BOWEL DISEASE VISUALIZATION OF EPIDEMIOLOGY STUDIES IN THE 21ST CENTURY (GIVES-21) CONSORTIUM
OBJECTIVE:The rapid emergence of IBD in newly industrialized regions supports the importance of environmental risk factors in disease etiology…
MONITORING IBD BY INTESTINAL ULTRASOUND DECREASES TIME TO TREATMENT CHANGE AND TIME TO REMISSION IN COMPARISON TO CONVENTIONAL MANAGEMENT: ANALYSIS OF PATIENTS WITH IBD ON MULTIPLE IBD THERAPIES
Intestinal ultrasound (IUS) is a non-invasive, repeatable, and accurate disease monitoring modality that can provide real-time assessment of inflammatory bowel disease (IBD)…